Literature DB >> 4020140

Prophylactic immunization against experimental leishmaniasis. IV. Subcutaneous immunization prevents the induction of protective immunity against fatal Leishmania major infection.

F Y Liew, C Hale, J G Howard.   

Abstract

Durable immunity against fatal L. major infection in genetically susceptible mice can be induced by immunization with 150,000-rad irradiated or heat-killed promastigotes administered i.v. or to a lesser extent i.p. Conversely, subcutaneous (s.c.) and intramuscular (i.m.) injections are not only totally ineffective but generally increase susceptibility to and enhance the progression of the disease, leading to earlier mortality. This detrimental effect is particularly evident with lower infecting challenge doses. Disease exacerbation is apparent in mice given 4 X s.c. injections of as few as 2 X 10(4) irradiated promastigotes, but it appears most potent after doses of 2 X 10(7). When mice given 4 X s.c. injections were subsequently immunized i.v. with 2 X 10(7) irradiated promastigotes, they failed to develop any evidence of protection against infection with 2 X 10(5) promastigotes, whereas mice given i.v. immunization alone were strongly protected. Thus, s.c. injections are capable of blocking the prophylactic effect of i.v. immunization with irradiated parasites. This inhibitory effect can be achieved with a single s.c. injection, although rather less potently than with four, and is even effective against four repeated weekly i.v. immunizations. Once induced, the effect persists undiminished after 100 days. A weaker effect is also inducible by s.c. injection given after i.v. immunization. The blocking effect of s.c. injection is not dependent on continuing viability of the promastigotes, as it can be induced equally readily with heat-killed, formalin-fixed, or sonicated parasites. The phenomenon extends to mouse strains genetically resistant as well as susceptible to L. major infection and, in congenic mice of BALB background, is independent of the major histocompatibility (H-2) gene complex.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4020140

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  Use of an attenuated leishmanial parasite as an immunoprophylactic and immunotherapeutic agent against murine visceral leishmaniasis.

Authors:  S Mukhopadhyay; S Bhattacharyya; R Majhi; T De; K Naskar; S Majumdar; S Roy
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

2.  Oral vaccination against coccidiosis: responses in strains of mice that differ in susceptibility to infection with Eimeria vermiformis.

Authors:  M E Rose; P Hesketh; D Wakelin
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

3.  Vaccine-induced immunity against cutaneous leishmaniasis in BALB/c mice.

Authors:  D Frommel; B W Ogunkolade; I Vouldoukis; L Monjour
Journal:  Infect Immun       Date:  1988-04       Impact factor: 3.441

4.  Evaluation of s.c. route of immunization by homologous radio attenuated live vaccine in experimental murine model of visceral leishmaniasis.

Authors:  Sanchita Datta; Supriya Khanra; Anindita Chakraborty; Syamal Roy; Madhumita Manna
Journal:  J Parasit Dis       Date:  2014-09-20

5.  Effect of CD4 monoclonal antibody in vivo on lesion development, delayed-type hypersensitivity and interleukin 3 production in experimental murine cutaneous leishmaniasis.

Authors:  F Y Liew; S Millott; R Lelchuk; S Cobbold; H Waldmann
Journal:  Clin Exp Immunol       Date:  1989-03       Impact factor: 4.330

6.  Immunization against experimental coccidiosis produces contrasting results in inbred mice of differing susceptibility to infection.

Authors:  M E Rose; P Hesketh; D Wakelin
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

7.  Protective effect of lectin from Synadenium carinatum on Leishmania amazonensis infection in BALB/c mice.

Authors:  Sandra R Afonso-Cardoso; Flavio H Rodrigues; Marcio A B Gomes; Adriano G Silva; Ademir Rocha; Aparecida H B Guimaraes; Ignes Candeloro; Silvio Favoreto; Marcelo S Ferreira; Maria A de Souza
Journal:  Korean J Parasitol       Date:  2007-12       Impact factor: 1.341

8.  Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK.

Authors:  Eduardo Fonseca Pinto; Roberta Olmo Pinheiro; Alice Rayol; Vicente Larraga; Bartira Rossi-Bergmann
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

9.  Induction of delayed-type hypersensitivity to Leishmania major and the concomitant acceleration of disease development in progressive murine cutaneous leishmaniasis.

Authors:  J S Dhaliwal; F Y Liew
Journal:  Infect Immun       Date:  1987-03       Impact factor: 3.441

10.  Mycobacterium bovis BCG-induced protection against cutaneous and systemic Leishmania major infections of mice.

Authors:  A H Fortier; B A Mock; M S Meltzer; C A Nacy
Journal:  Infect Immun       Date:  1987-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.